ResMed Inc. Common Stock (RMD)
245.78
-0.00 (-0.00%)
NYSE · Last Trade: May 22nd, 10:16 AM EDT
RBC Capital noted that ResMed now has “a number of competitive threats on the horizon."
Via Stocktwits · May 20, 2025
Get insights into the top gainers and losers in the S&P500 index of Tuesday's pre-market session.
Via Chartmill · May 20, 2025
Wall Street has issued downbeat forecasts for the stocks in this article.
These predictions are rare - financial institutions typically hesitate to say bad things about a company because it can jeopardize their other revenue-generating business lines like M&A advisory.
Via StockStory · May 20, 2025
RESMED INC (NYSE:RMD) is a high-quality stock with strong revenue growth, exceptional profitability, and a solid balance sheet, making it a standout pick for long-term investors.
Via Chartmill · May 19, 2025
Via The Motley Fool · May 18, 2025
Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at ResMed (NYSE:RMD) and the best and worst performers in the patient monitoring industry.
Via StockStory · May 14, 2025
Companies with solid operating margins have a competitive edge, allowing them to reinvest for sustainable expansion.
The best of these businesses balance profitability with reinvestment, setting themselves up for long-term success.
Via StockStory · May 6, 2025
Seeking insights into today's market movers? Discover the S&P500 gap up and gap down stocks in today's session on Monday. Stay informed about the latest market trends.
Via Chartmill · April 28, 2025
Medical device company ResMed (NYSE:RMD) met Wall Street’s revenue expectations in Q1 CY2025, with sales up 7.9% year on year to $1.29 billion. Its non-GAAP profit of $2.37 per share was in line with analysts’ consensus estimates.
Via StockStory · April 26, 2025
Wondering what's happening in today's session for the S&P500 index? Stay informed with the top movers within the S&P500 index on Thursday.
Via Chartmill · April 24, 2025
ResMed posted Q3 EPS of $2.37 on $1.29 billion in sales, citing strong global demand for sleep devices, plus a boost from tariff exemptions.
Via Benzinga · April 24, 2025
Get insights into the S&P500 index performance on Thursday. Explore the top gainers and losers within the S&P500 index in today's session.
Via Chartmill · April 24, 2025
Via Benzinga · April 24, 2025
Wondering which stocks are making significant price gaps? Explore the S&P500 index on Thursday to find the gap up and gap down stocks in today's session.
Via Chartmill · April 24, 2025
Via Benzinga · April 24, 2025
U.S. equities are pushing higher for a third straight session, eyeing the longest winning streak since the Trump tariff announcement on April 2, as optimism over corporate earnings and easing trade tensions boosts risk sentiment.
Via Benzinga · April 24, 2025
Revenue for the three months through the end of March rose 8% to $1.29 billion, in line with analyst estimates.
Via Stocktwits · April 24, 2025
After the closing bell on Wednesday, let's take a glimpse of the US markets and explore the top S&P500 gainers and losers in today's after-hours session.
Via Chartmill · April 23, 2025
Medical device company ResMed (NYSE:RMD) met Wall Street’s revenue expectations in Q1 CY2025, with sales up 7.9% year on year to $1.29 billion. Its non-GAAP profit of $2.37 per share was in line with analysts’ consensus estimates.
Via StockStory · April 23, 2025
Risk-on sentiment dominated Wall Street on Wednesday, as upbeat earnings reports and conciliatory messages from the Trump administration helped lift investor confidence.
Via Benzinga · April 23, 2025
Medical device company ResMed (NYSE:RMD)
will be announcing earnings results tomorrow after market close. Here’s what to look for.
Via StockStory · April 22, 2025
Uncovering Dividend Opportunities with RESMED INC (NYSE:RMD).
Via Chartmill · April 15, 2025